Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Phase 2

Recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Sotatercept

First Posted Date: 2022-10-20

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 42

Registration Number: NCT05587712

Locations: 🇺🇸
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California, United States
🇺🇸
Stanford University School of Medicine ( Site 1603), Palo Alto, California, United States
🇺🇸
UCSF Benioff Children's Hospital San Francisco ( Site 1611), San Francisco, California, United States

and more 32 locations

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: V116
Biological: PPSV23

First Posted Date: 2022-10-06

Last Posted Date: 2025-03-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1484

Registration Number: NCT05569954

Locations: 🇩🇪
Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901), Hamburg, Germany
🇰🇷
Asan Medical Center ( Site 1809), Seoul, Korea, Republic of
🇰🇷
Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805), Seoul, Korea, Republic of

and more 52 locations

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Biological: Zilovertamab vedotin

First Posted Date: 2022-10-03

Last Posted Date: 2024-11-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 40

Registration Number: NCT05562830

Locations: 🇨🇱
FALP-UIDO ( Site 1151), Santiago, Region M. De Santiago, Chile
🇮🇱
Rambam Health Care Campus-Oncology ( Site 1501), Haifa, Israel
🇺🇸
Cleveland Clinic-Taussig Cancer Center ( Site 1036), Cleveland, Ohio, United States

and more 15 locations

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Phase 2

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Drug: Molnupiravir
Drug: Placebo
Biological: RSV A Memphis 37b

First Posted Date: 2022-09-29

Last Posted Date: 2024-05-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 116

Registration Number: NCT05559905

Locations: 🇬🇧
hVIVO Services ( Site 0001), London, London, City Of, United Kingdom

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Phase 3

Completed

Conditions: Pneumonia, Pneumococcal

Interventions: Biological: V116
Biological: QIV
Biological: Matching Placebo for V116

First Posted Date: 2022-09-02

Last Posted Date: 2023-06-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1080

Registration Number: NCT05526716

Locations: 🇺🇸
Optimal Research ( Site 0008), Melbourne, Florida, United States
🇺🇸
Holston Medical Group-Clinical Research ( Site 0009), Kingsport, Tennessee, United States
🇺🇸
Triple O Research Institute, P.A ( Site 0054), West Palm Beach, Florida, United States

and more 53 locations

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Lenvatinib
Biological: Pembrolizumab
Drug: Placebo

First Posted Date: 2022-08-31

Last Posted Date: 2025-04-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 112

Registration Number: NCT05523323

Locations: 🇨🇳
Shanghai East Hospital ( Site 3300), Shanghai, Shanghai, China
🇨🇳
Henan Cancer Hospital ( Site 3309), Zhengzhou, Henan, China
🇨🇳
Chongqing Cancer Hospital ( Site 3327), Chongqing, Chongqing, China

and more 25 locations

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

Phase 1

Active, not recruiting

Conditions: Advanced/Metastatic Solid Tumors
Neoplasms

Interventions: Biological: MK-4464
Biological: Pembrolizumab
Drug: 89Zr-MK-4464

First Posted Date: 2022-08-24

Last Posted Date: 2024-11-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 260

Registration Number: NCT05514444

Locations: 🇨🇦
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201), Toronto, Ontario, Canada
🇺🇸
The University of Louisville, James Graham Brown Cancer Center ( Site 0100), Louisville, Kentucky, United States
🇳🇱
Amsterdam UMC, locatie VUmc ( Site 0400), Amsterdam, Noord-Holland, Netherlands

and more 3 locations

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma

Interventions: Biological: favezelimab/pembrolizumab
Drug: bendamustine
Drug: gemcitabine

First Posted Date: 2022-08-19

Last Posted Date: 2025-05-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 200

Registration Number: NCT05508867

Locations: 🇨🇳
Sun Yat-sen University Cancer Center ( Site 0500), Guangzhou, Guangdong, China
🇺🇸
The University of Arizona Cancer Center - North Campus ( Site 2216), Tucson, Arizona, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 2208), Los Angeles, California, United States

and more 102 locations

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Phase 2

Completed

Conditions: Dengue Virus
Dengue Disease

Interventions: Biological: V181 Low-Potency Level
Biological: Placebo
Biological: V181 Mid-Potency Level
Biological: V181 High-Potency Level

First Posted Date: 2022-08-19

Last Posted Date: 2025-05-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1271

Registration Number: NCT05507450

Locations: 🇺🇸
Advanced Medical Research Institute ( Site 0115), Miami, Florida, United States
🇦🇺
Emeritus Research ( Site 0009), Camberwell, Victoria, Australia
🇫🇮
FVR, Porin rokotetutkimusklinikka ( Site 0033), Pori, Satakunta, Finland

and more 29 locations

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: MK-8527

First Posted Date: 2022-08-10

Last Posted Date: 2025-03-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT05494736

Locations: 🇷🇴
ARENSIA Exploratory Medicine-Institutul National de Boli Infectioase Matei Bals ( Site 0004), București, Bucuresti, Romania
🇿🇦
Desmond Tutu Health Foundation ( Site 0001), Cape Town, Western Cape, South Africa
🇿🇦
Josha Research ( Site 0003), Bloemfontein, Free State, South Africa

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy